Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2008 1
2009 2
2010 5
2011 5
2012 6
2013 8
2014 6
2015 7
2016 7
2017 4
2018 3
2019 3
2020 7
2021 13
2022 9
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Error-suppression mechanism of PCR by blocker strands.
Aoyanagi H, Pigolotti S, Ono S, Toyabe S. Aoyanagi H, et al. Among authors: ono s. Biophys J. 2023 Apr 4;122(7):1334-1341. doi: 10.1016/j.bpj.2023.02.028. Epub 2023 Feb 23. Biophys J. 2023. PMID: 36823986 Free PMC article.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Genetic and epigenetic analyses of panic disorder in the post-GWAS era.
Morimoto Y, Ono S, Kurotaki N, Imamura A, Ozawa H. Morimoto Y, et al. Among authors: ono s. J Neural Transm (Vienna). 2020 Nov;127(11):1517-1526. doi: 10.1007/s00702-020-02205-y. Epub 2020 May 9. J Neural Transm (Vienna). 2020. PMID: 32388794 Free PMC article. Review.
Effects of internal limiting membrane peeling on anatomical and functional outcomes in macula-off rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy: Japan-Retinal Detachment Registry.
Obata S, Sawada O, Kakinoki M, Matsumoto R, Saishin Y, Ohji M; Japan-Retinal Detachment Registry Group. Obata S, et al. Jpn J Ophthalmol. 2023 Jul;67(4):417-423. doi: 10.1007/s10384-023-01000-y. Epub 2023 Jun 8. Jpn J Ophthalmol. 2023. PMID: 37289298
79 results